GlaxoSmithKline plc (LON:GSK)‘s stock had its “neutral” rating reiterated by equities research analysts at JPMorgan Chase & Co. in a research note issued on Thursday.

A number of other equities analysts have also weighed in on the company. Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline plc in a research note on Wednesday, July 27th. BNP Paribas restated a “neutral” rating and issued a GBX 1,430 ($18.67) target price on shares of GlaxoSmithKline plc in a research report on Sunday, July 3rd. Goldman Sachs Group Inc. restated a “buy” rating and issued a GBX 1,800 ($23.50) target price on shares of GlaxoSmithKline plc in a research report on Tuesday, July 12th. Citigroup Inc. restated a “buy” rating on shares of GlaxoSmithKline plc in a research report on Thursday, June 23rd. Finally, Morgan Stanley lifted their target price on GlaxoSmithKline plc from GBX 1,500 ($19.58) to GBX 1,650 ($21.54) and gave the company an “equal weight” rating in a research report on Monday, July 11th. Three investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and eight have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of GBX 1,676.44 ($21.88).

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1629.50 on Thursday. GlaxoSmithKline plc has a 12 month low of GBX 1,227.50 and a 12 month high of GBX 1,716.50. The company’s 50-day moving average price is GBX 1,654.01 and its 200-day moving average price is GBX 1,531.21. The company’s market cap is GBX 79.21 billion.

The business also recently disclosed a dividend, which will be paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th will be given a dividend of GBX 19 ($0.25) per share. The ex-dividend date of this dividend is Thursday, August 11th. This represents a yield of 1.12%.

In other news, insider Witty,Sir Andrew P sold 10,000 shares of the stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($22.10), for a total transaction of £169,300 ($220,989.43). Also, insider Slaoui,Moncef bought 28 shares of the business’s stock in a transaction dated Friday, August 12th. The shares were acquired at an average cost of GBX 2,208 ($28.82) per share, with a total value of £618.24 ($807.00).

About GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.